These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

260 related items for PubMed ID: 28890368

  • 1. CYP17A1-independent production of the neurosteroid-derived 5α-pregnan-3β,6α-diol-20-one in androgen-responsive prostate cancer cell lines under serum starvation and inhibition by Abiraterone.
    de Mello Martins AGG, Allegretta G, Unteregger G, Haupenthal J, Eberhard J, Hoffmann M, van der Zee JA, Junker K, Stöckle M, Müller R, Hartmann RW, Ohlmann CH.
    J Steroid Biochem Mol Biol; 2017 Nov; 174():183-191. PubMed ID: 28890368
    [Abstract] [Full Text] [Related]

  • 2. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors.
    Cai C, Chen S, Ng P, Bubley GJ, Nelson PS, Mostaghel EA, Marck B, Matsumoto AM, Simon NI, Wang H, Chen S, Balk SP.
    Cancer Res; 2011 Oct 15; 71(20):6503-13. PubMed ID: 21868758
    [Abstract] [Full Text] [Related]

  • 3. Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer.
    Li Z, Bishop AC, Alyamani M, Garcia JA, Dreicer R, Bunch D, Liu J, Upadhyay SK, Auchus RJ, Sharifi N.
    Nature; 2015 Jul 16; 523(7560):347-51. PubMed ID: 26030522
    [Abstract] [Full Text] [Related]

  • 4. Dihydrotestosterone synthesis pathways from inactive androgen 5α-androstane-3β,17β-diol in prostate cancer cells: Inhibition of intratumoural 3β-hydroxysteroid dehydrogenase activities by abiraterone.
    Ando T, Nishiyama T, Takizawa I, Ishizaki F, Miyashiro Y, Takeda K, Hara N, Tomita Y.
    Sci Rep; 2016 Aug 26; 6():32198. PubMed ID: 27561382
    [Abstract] [Full Text] [Related]

  • 5. Abiraterone inhibits 3β-hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer.
    Li R, Evaul K, Sharma KK, Chang KH, Yoshimoto J, Liu J, Auchus RJ, Sharifi N.
    Clin Cancer Res; 2012 Jul 01; 18(13):3571-9. PubMed ID: 22753664
    [Abstract] [Full Text] [Related]

  • 6. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants.
    Mostaghel EA, Marck BT, Plymate SR, Vessella RL, Balk S, Matsumoto AM, Nelson PS, Montgomery RB.
    Clin Cancer Res; 2011 Sep 15; 17(18):5913-25. PubMed ID: 21807635
    [Abstract] [Full Text] [Related]

  • 7. CYP17A1 exhibits 17αhydroxylase/17,20-lyase activity towards 11β-hydroxyprogesterone and 11-ketoprogesterone metabolites in the C11-oxy backdoor pathway.
    van Rooyen D, Yadav R, Scott EE, Swart AC.
    J Steroid Biochem Mol Biol; 2020 May 15; 199():105614. PubMed ID: 32007561
    [Abstract] [Full Text] [Related]

  • 8. Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys.
    Yamaoka M, Hara T, Hitaka T, Kaku T, Takeuchi T, Takahashi J, Asahi S, Miki H, Tasaka A, Kusaka M.
    J Steroid Biochem Mol Biol; 2012 Apr 15; 129(3-5):115-28. PubMed ID: 22249003
    [Abstract] [Full Text] [Related]

  • 9. Human saturated steroid 6alpha-hydroxylase.
    Dombroski R, Casey ML, Macdonald PC.
    J Clin Endocrinol Metab; 1997 May 15; 82(5):1338-44. PubMed ID: 9141513
    [Abstract] [Full Text] [Related]

  • 10. Assessment of steroidogenesis and steroidogenic enzyme functions.
    Luu-The V.
    J Steroid Biochem Mol Biol; 2013 Sep 15; 137():176-82. PubMed ID: 23770321
    [Abstract] [Full Text] [Related]

  • 11. A-ring modified steroidal azoles retaining similar potent and slowly reversible CYP17A1 inhibition as abiraterone.
    Garrido M, Peng HM, Yoshimoto FK, Upadhyay SK, Bratoeff E, Auchus RJ.
    J Steroid Biochem Mol Biol; 2014 Sep 15; 143():1-10. PubMed ID: 24508512
    [Abstract] [Full Text] [Related]

  • 12. Next-generation steroidogenesis inhibitors, dutasteride and abiraterone, attenuate but still do not eliminate androgen biosynthesis in 22RV1 cells in vitro.
    Pham S, Deb S, Ming DS, Adomat H, Hosseini-Beheshti E, Zoubeidi A, Gleave M, Guns ES.
    J Steroid Biochem Mol Biol; 2014 Oct 15; 144 Pt B():436-44. PubMed ID: 25201454
    [Abstract] [Full Text] [Related]

  • 13. Glucuronidation of Abiraterone and Its Pharmacologically Active Metabolites by UGT1A4, Influence of Polymorphic Variants and Their Potential as Inhibitors of Steroid Glucuronidation.
    Vaillancourt J, Turcotte V, Caron P, Villeneuve L, Lacombe L, Pouliot F, Lévesque É, Guillemette C.
    Drug Metab Dispos; 2020 Feb 15; 48(2):75-84. PubMed ID: 31727674
    [Abstract] [Full Text] [Related]

  • 14. A bypass mechanism of abiraterone-resistant prostate cancer: Accumulating CYP17A1 substrates activate androgen receptor signaling.
    Moll JM, Kumagai J, van Royen ME, Teubel WJ, van Soest RJ, French PJ, Homma Y, Jenster G, de Wit R, van Weerden WM.
    Prostate; 2019 Jun 15; 79(9):937-948. PubMed ID: 31017696
    [Abstract] [Full Text] [Related]

  • 15. Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy.
    Li Z, Alyamani M, Li J, Rogacki K, Abazeed M, Upadhyay SK, Balk SP, Taplin ME, Auchus RJ, Sharifi N.
    Nature; 2016 May 26; 533(7604):547-51. PubMed ID: 27225130
    [Abstract] [Full Text] [Related]

  • 16. Pathways and genes involved in steroid hormone metabolism in male pigs: a review and update.
    Robic A, Faraut T, Prunier A.
    J Steroid Biochem Mol Biol; 2014 Mar 26; 140():44-55. PubMed ID: 24239507
    [Abstract] [Full Text] [Related]

  • 17. Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer.
    Hofland J, van Weerden WM, Dits NF, Steenbergen J, van Leenders GJ, Jenster G, Schröder FH, de Jong FH.
    Cancer Res; 2010 Feb 01; 70(3):1256-64. PubMed ID: 20086173
    [Abstract] [Full Text] [Related]

  • 18. Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer.
    Attard G, Reid AH, Auchus RJ, Hughes BA, Cassidy AM, Thompson E, Oommen NB, Folkerd E, Dowsett M, Arlt W, de Bono JS.
    J Clin Endocrinol Metab; 2012 Feb 01; 97(2):507-16. PubMed ID: 22170708
    [Abstract] [Full Text] [Related]

  • 19. Prostate cancer androgen biosynthesis relies solely on CYP17A1 downstream metabolites.
    Snaterse G, Taylor AE, Moll JM, O'Neil DM, Teubel WJ, van Weerden WM, Arlt W, Hofland J.
    J Steroid Biochem Mol Biol; 2024 Feb 01; 236():106446. PubMed ID: 38104728
    [Abstract] [Full Text] [Related]

  • 20. Limited in vitro efficacy of CYP17A1 inhibition on human castration resistant prostate cancer.
    Kosaka T, Miyajima A, Yasumizu Y, Miyazaki Y, Kikuchi E, Oya M.
    Steroids; 2014 Dec 01; 92():39-44. PubMed ID: 25150014
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.